Quick Answer
ADMA BIOLOGICS, INC. reported Net Income Loss of $146.93 million for the year ending 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -25.7% in Net Income Loss from 2024 to 2025.
- This data is from ADMA BIOLOGICS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), ADMA BIOLOGICS, INC.'s Net Income Loss has grown by 2,588.9%.
- Historical annual values: Fiscal year 2025: $146.93 million | Fiscal year 2024: $197.67 million | Fiscal year 2023: -$28.24 million | Fiscal year 2022: -$65.90 million | Fiscal year 2021: -$71.65 million | Fiscal year 2020: -$75.75 million | Fiscal year 2019: -$48.28 million | Fiscal year 2018: -$65.74 million | Fiscal year 2017: -$43.76 million | Fiscal year 2016: -$19.52 million | Fiscal year 2015: -$17.97 million | Fiscal year 2014: -$16.81 million | Fiscal year 2013: -$15.53 million | Fiscal year 2012: -$7.30 million | Fiscal year 2011: -$5.90 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: